| aflibercept | Regeneron | ||
| 2mg/0.05ml; Intravitreal Injection |
More Than $1000 mn
|
||
| None |
Less Than 5
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD) | |||
|
Yes
| |||
| Eylea | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 | Patent 35 | Patent 36 | Patent 37 | Patent 38 | Patent 39 | Patent 40 | Patent 41 | Patent 42 | Patent 43 | Patent 44 | Patent 45 | Patent 46 | Patent 47 | Patent 48 | Patent 49 | Patent 50 | Patent 51 | Patent 52 | Patent 53 | Patent 54 | Patent 55 | Patent 56 | Patent 57 | Patent 58 | Patent 59 | Patent 60 | Patent 61 | Patent 62 | Patent 63 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** *************** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** ** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** ** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** ** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ***** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ******* ******* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** *************** | ******* / ********* **** ** ** | **** | ***** *** **** | ||
| ***** | ******* | **** | *** ***** ** ******* | ||
| ******* ******* | ******* | **** | *** ***** ** ******* |
Download ParaIV Report